SINGAPORE (Feb 5): Emerging areas of precision medicine could transform loss-making healthcare group Clearbridge Health into a “potential unicorn in the making”, according to Tayrona Financial, the independent equity research house formerly known as NRA Capital.

“We see high growth potential for the company as doctors increasingly customise treatments to patients’ genetic composition,” says analyst Liu Jinshu in a Jan 31 report. “With its network across Asia, Clearbridge is positioning itself to tap on this trend over the next five to ten years.”

According to Liu, such growing markets in precision medicine include direct-to-consumer DNA tests, drug sensitivity testing and cancer treatment.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook